Eli Lilly and Co.

Eli Lilly develops and commercializes prescription pharmaceuticals across therapeutic areas including diabetes, oncology, immunology, and neuroscience. The company's revenue drivers include blockbuster drugs like Mounjaro and Trulicity for diabetes, Verzenio for breast cancer, and emerging obesity treatments. Lilly operates through direct sales to healthcare providers, hospitals, and pharmacy benefit managers. Its business model relies on patent-protected drugs with high margins, funded by substantial R&D investment to maintain a pipeline of innovative therapies.

Eli Lilly benefits from robust demand for GLP-1 diabetes and obesity drugs, which have driven exceptional revenue growth and margin expansion. The stock trades at a premium P/E due to strong earnings momentum and pipeline potential. Key risks include patent expirations on major drugs, regulatory hurdles for new therapies, and pricing pressure from government negotiations. Clinical trial failures or manufacturing challenges could also impact growth expectations embedded in the valuation.

Lilly competes with Novo Nordisk in the diabetes and obesity market (Ozempic, Wegovy), Pfizer across oncology and general pharmaceuticals, Merck in cancer immunotherapy, AbbVie in immunology, and Roche in biologics and cancer treatments. The GLP-1 obesity drug market has become particularly competitive, with multiple companies racing to capture market share.

Eli Lilly has maintained uninterrupted dividend payments since 1885, one of the longest streaks in corporate America. The company raises its dividend annually, though the yield remains modest as the stock price has appreciated significantly. Lilly balances shareholder returns with reinvestment in R&D and acquisitions, positioning dividends as a supplement to capital gains rather than the primary return driver.

LLY last closed at $1,417.99, up 0.61% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $809.63 and a high of $1,408.38. The current price represents 100% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 36 analysts covering LLY, the consensus rating is Strong Buy — 31 rate it a buy, 4 hold, and 1 sell. The average price target sits at $1,330.33, implying 6% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Eli Lilly and Co. generated $68.54B in revenue during fiscal year 2026, with $21.70B reaching the bottom line as net income. The net profit margin of 31.7% is strong by most industry standards.

LLY trades at a P/E ratio of 50.18 on trailing earnings of $29.80 per share. That's well above the S&P 500 historical average of ~20-25x, which typically signals that investors are pricing in aggressive future growth. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

LLY has been on a strong uptrend over the past year and continues to show momentum. Returns by timeframe: +0.00% (1D), +3.22% (1W), +22.51% (1M), +19.59% (3M), +46.64% (6M), +53.16% (1Y), +31.25% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether LLY is outperforming or lagging the broader market.